Immunovant Other Current Assets

Immunovant (IMVT) currently reports a other current assets of $43M as of March 2026. That compares with $52M in the prior-year period — down 17.1% year over year. Use the charts on this page to explore Immunovant's other current assets history and peer comparisons.

Immunovant's other current assets decreased from $52M to $43M — a 17.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Immunovant reported $43M in other current assets as of March 2026. That compares with $52M in the prior-year period — down 17.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $43M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Immunovant, and consider following IMVT for alerts when major investors trade the stock.

Immunovant is classified in the Healthcare sector. On other current assets, it currently shows $43M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMVT with unrelated industries.